ProKidney (PROK) Competitors $1.70 +0.06 (+3.33%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PROK vs. DNAB, DNAD, VPCB, FLYA, LGST, NAMS, CNTA, IRON, HRMY, and EVOShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Social Capital Suvretta Holdings Corp. II (DNAB), Social Capital Suvretta Holdings Corp. IV (DNAD), VPC Impact Acquisition Holdings II (VPCB), SOAR Technology Acquisition (FLYA), Semper Paratus Acquisition (LGST), NewAmsterdam Pharma (NAMS), Centessa Pharmaceuticals (CNTA), Disc Medicine (IRON), Harmony Biosciences (HRMY), and Evotec (EVO). ProKidney vs. Social Capital Suvretta Holdings Corp. II Social Capital Suvretta Holdings Corp. IV VPC Impact Acquisition Holdings II SOAR Technology Acquisition Semper Paratus Acquisition NewAmsterdam Pharma Centessa Pharmaceuticals Disc Medicine Harmony Biosciences Evotec ProKidney (NASDAQ:PROK) and Social Capital Suvretta Holdings Corp. II (NASDAQ:DNAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Which has stronger valuation & earnings, PROK or DNAB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-3.00Social Capital Suvretta Holdings Corp. IIN/AN/A$2.74MN/AN/A Which has more risk and volatility, PROK or DNAB? ProKidney has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Social Capital Suvretta Holdings Corp. II has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Do insiders & institutionals believe in PROK or DNAB? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 76.6% of Social Capital Suvretta Holdings Corp. II shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor PROK or DNAB? In the previous week, ProKidney had 4 more articles in the media than Social Capital Suvretta Holdings Corp. II. MarketBeat recorded 4 mentions for ProKidney and 0 mentions for Social Capital Suvretta Holdings Corp. II. ProKidney's average media sentiment score of 0.67 beat Social Capital Suvretta Holdings Corp. II's score of 0.00 indicating that ProKidney is being referred to more favorably in the media. Company Overall Sentiment ProKidney Positive Social Capital Suvretta Holdings Corp. II Neutral Is PROK or DNAB more profitable? ProKidney's return on equity of 0.00% beat Social Capital Suvretta Holdings Corp. II's return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Social Capital Suvretta Holdings Corp. II N/A -73.34%2.13% Do analysts recommend PROK or DNAB? ProKidney currently has a consensus target price of $4.50, indicating a potential upside of 172.73%. Given ProKidney's stronger consensus rating and higher possible upside, equities research analysts plainly believe ProKidney is more favorable than Social Capital Suvretta Holdings Corp. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Social Capital Suvretta Holdings Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor PROK or DNAB? ProKidney received 8 more outperform votes than Social Capital Suvretta Holdings Corp. II when rated by MarketBeat users. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% Social Capital Suvretta Holdings Corp. IIN/AN/A SummaryProKidney beats Social Capital Suvretta Holdings Corp. II on 9 of the 12 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$477.96M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.18%4.07%P/E Ratio-3.0045.61126.3217.81Price / SalesN/A359.341,179.2574.56Price / CashN/A160.0933.8632.53Price / Book-0.343.734.684.68Net Income-$35.47M-$41.63M$119.54M$226.08M7 Day Performance-23.26%-4.73%-1.83%-1.04%1 Month Performance-11.76%-6.53%-3.60%1.04%1 Year Performance-11.29%25.63%31.91%26.28% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney2.5946 of 5 stars$1.71+3.3%$4.50+163.9%-6.3%$493.89MN/A-3.103News CoverageDNABSocial Capital Suvretta Holdings Corp. IIN/A$10.35+0.1%N/A+0.0%$330.06MN/A0.004DNADSocial Capital Suvretta Holdings Corp. IVN/A$10.35flatN/A+0.0%$330.06MN/A0.004VPCBVPC Impact Acquisition Holdings IIN/A$10.28flatN/A+0.0%$328.55MN/A0.007FLYASOAR Technology AcquisitionN/A$10.41-0.4%N/A+0.0%$319.24MN/A0.002,021High Trading VolumeLGSTSemper Paratus AcquisitionN/A$4.51flatN/A-58.9%$71.35MN/A0.002,021Gap UpIRONDisc Medicine3.1676 of 5 stars$63.33+1.2%$85.80+35.5%+22.4%$1.88BN/A0.0078Insider TradeAnalyst RevisionCNTACentessa Pharmaceuticals4.06 of 5 stars$16.53-1.3%$25.83+56.3%+144.7%$1.87B$6.85M0.0072HRMYHarmony Biosciences4.7919 of 5 stars$32.68-0.3%$47.00+43.8%+18.1%$1.86B$582.02M15.64200EVOEvotec1.9292 of 5 stars$5.23-1.3%$5.93+13.4%-49.7%$1.85B$845.74M0.005,061TARSTarsus Pharmaceuticals1.8691 of 5 stars$45.77-1.7%$54.20+18.4%+166.2%$1.75B$17.45M-12.2350Analyst Revision Related Companies and Tools Related Companies DNAB Alternatives DNAD Alternatives VPCB Alternatives FLYA Alternatives LGST Alternatives NAMS Alternatives CNTA Alternatives IRON Alternatives HRMY Alternatives EVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.